Cargando…

Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin

Background Urinary tract infections (UTIs) are common in patients with diabetes. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to achieve good glycemic control increases glucose levels in urine. This glycosuria further enhances the risk of UTIs. This study aimed to evaluate the frequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sarfaraz, Hashmi, Mubashar Sultan, Rana, Muhammad A, Zafar, Ghulam Mujtaba, Asif, Sadia, Farooq, Muhammad Talha, Zahoor, Sarmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887691/
https://www.ncbi.nlm.nih.gov/pubmed/35251794
http://dx.doi.org/10.7759/cureus.21720
_version_ 1784660959061606400
author Khan, Sarfaraz
Hashmi, Mubashar Sultan
Rana, Muhammad A
Zafar, Ghulam Mujtaba
Asif, Sadia
Farooq, Muhammad Talha
Zahoor, Sarmad
author_facet Khan, Sarfaraz
Hashmi, Mubashar Sultan
Rana, Muhammad A
Zafar, Ghulam Mujtaba
Asif, Sadia
Farooq, Muhammad Talha
Zahoor, Sarmad
author_sort Khan, Sarfaraz
collection PubMed
description Background Urinary tract infections (UTIs) are common in patients with diabetes. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to achieve good glycemic control increases glucose levels in urine. This glycosuria further enhances the risk of UTIs. This study aimed to evaluate the frequency of UTIs in patients with type 2 diabetes receiving the SGLT2i dapagliflozin as an add-on therapy. Methods We conducted this cross-sectional study at the Endocrinology Department of Hayatabad Medical Complex in Peshawar from April 2020 to September 2020. A total of 400 patients with diabetes receiving either 5 mg or 10 mg of dapagliflozin as an add-on therapy for the treatment of type 2 diabetes were included in this study. We collected blood and urine samples from participants and measured glycosylated hemoglobin levels. Urine samples were cultured on cysteine lactose electrolyte deficient agar. We used IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY) to analyze our data. Results The prevalence of UTIs in diabetic patients receiving 5 mg or 10 mg of dapagliflozin was 5.3%. Women were more affected (76.2%) than men (p < 0.05). UTIs were more prevalent in patients older than 50 years (85.7%) than in any other age group. The dose strength of dapagliflozin was not associated with UTIs (p > 0.05). Conclusion This study examined UTIs in patients taking dapagliflozin for the treatment of type 2 diabetes. These infections were mild to moderate and were treated easily. None of these infections caused the patient to discontinue the treatment. Dapagliflozin is well-tolerated in patients with diabetes but should be used with appropriate caution and monitoring.
format Online
Article
Text
id pubmed-8887691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88876912022-03-03 Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin Khan, Sarfaraz Hashmi, Mubashar Sultan Rana, Muhammad A Zafar, Ghulam Mujtaba Asif, Sadia Farooq, Muhammad Talha Zahoor, Sarmad Cureus Endocrinology/Diabetes/Metabolism Background Urinary tract infections (UTIs) are common in patients with diabetes. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to achieve good glycemic control increases glucose levels in urine. This glycosuria further enhances the risk of UTIs. This study aimed to evaluate the frequency of UTIs in patients with type 2 diabetes receiving the SGLT2i dapagliflozin as an add-on therapy. Methods We conducted this cross-sectional study at the Endocrinology Department of Hayatabad Medical Complex in Peshawar from April 2020 to September 2020. A total of 400 patients with diabetes receiving either 5 mg or 10 mg of dapagliflozin as an add-on therapy for the treatment of type 2 diabetes were included in this study. We collected blood and urine samples from participants and measured glycosylated hemoglobin levels. Urine samples were cultured on cysteine lactose electrolyte deficient agar. We used IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY) to analyze our data. Results The prevalence of UTIs in diabetic patients receiving 5 mg or 10 mg of dapagliflozin was 5.3%. Women were more affected (76.2%) than men (p < 0.05). UTIs were more prevalent in patients older than 50 years (85.7%) than in any other age group. The dose strength of dapagliflozin was not associated with UTIs (p > 0.05). Conclusion This study examined UTIs in patients taking dapagliflozin for the treatment of type 2 diabetes. These infections were mild to moderate and were treated easily. None of these infections caused the patient to discontinue the treatment. Dapagliflozin is well-tolerated in patients with diabetes but should be used with appropriate caution and monitoring. Cureus 2022-01-29 /pmc/articles/PMC8887691/ /pubmed/35251794 http://dx.doi.org/10.7759/cureus.21720 Text en Copyright © 2022, Khan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Khan, Sarfaraz
Hashmi, Mubashar Sultan
Rana, Muhammad A
Zafar, Ghulam Mujtaba
Asif, Sadia
Farooq, Muhammad Talha
Zahoor, Sarmad
Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title_full Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title_fullStr Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title_full_unstemmed Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title_short Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
title_sort frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887691/
https://www.ncbi.nlm.nih.gov/pubmed/35251794
http://dx.doi.org/10.7759/cureus.21720
work_keys_str_mv AT khansarfaraz frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT hashmimubasharsultan frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT ranamuhammada frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT zafarghulammujtaba frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT asifsadia frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT farooqmuhammadtalha frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin
AT zahoorsarmad frequencyofurinarytractinfectionsintype2diabeticpatientstakingdapagliflozin